Dose Design: Bridging Early- And Late-Phase Development
With mounting pressure on innovators to achieve faster timelines and reduce development costs, clinical dose strategies in Phase 1 and 2 are often different from the final commercialized dose form. As companies transition to late-phase development, they must look beyond establishing proof of concept and consider patient needs, scalability and market variables to be successful. It is increasingly important for companies to understand the strategies they can utilize to streamline early-phase development while simultaneously preparing for commercial success. This webcast will discuss key concepts that should be addressed as a molecule advances through the clinical development phases.